ACIU Historical Financial Ratios
| ACIU Stock | USD 3.38 0.09 2.74% |
AC Immune is presently reporting on over 121 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 2.11 or Days Sales Outstanding of 390 will help investors to properly organize and evaluate AC Immune financial condition quickly.
ACIU |
About ACIU Financial Ratios Analysis
AC ImmuneFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate AC Immune investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on ACIU financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across AC Immune history.
AC Immune Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing AC Immune stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on AC Immune sales, a figure that is much harder to manipulate than other AC Immune multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is AC Immune dividend as a percentage of AC Immune stock price. AC Immune dividend yield is a measure of AC Immune stock productivity, which can be interpreted as interest rate earned on an AC Immune investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Earnings Yield
The inverse of the price-to-earnings ratio, representing the percentage of each dollar invested in the stock that was earned by the company.Most ratios from AC Immune's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into AC Immune current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.At this time, AC Immune's Current Ratio is comparatively stable compared to the past year. Tangible Book Value Per Share is likely to gain to 1.57 in 2024, whereas Free Cash Flow Yield is likely to drop (0.18) in 2024.
| 2021 | 2023 | 2024 (projected) | Days Sales Outstanding | 74.21 | 371.04 | 389.59 | PTB Ratio | 1.46 | 2.22 | 2.11 |
AC Immune fundamentals Correlations
Click cells to compare fundamentals
AC Immune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AC Immune fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 79.92 | 5.24 | 21.33 | 40.03 | 24.06 | 38.71 | |
| Ptb Ratio | 2.14 | 1.53 | 1.46 | 0.93 | 2.22 | 2.11 | |
| Days Sales Outstanding | 208.12 | 3.6 | 37.63 | 74.21 | 371.04 | 389.59 | |
| Book Value Per Share | 3.86 | 3.0 | 3.1 | 2.02 | 1.9 | 1.7 | |
| Free Cash Flow Yield | 0.0917 | (0.19) | (0.2) | (0.47) | (0.17) | (0.18) | |
| Operating Cash Flow Per Share | (0.39) | (0.71) | 0.78 | (0.83) | (0.88) | (0.75) | |
| Stock Based Compensation To Revenue | 0.35 | 0.0255 | 0.26 | 0.85 | 0.29 | 0.16 | |
| Capex To Depreciation | 1.11 | 0.87 | 1.1 | 0.53 | 0.36 | 0.34 | |
| Pb Ratio | 2.14 | 1.53 | 1.46 | 0.93 | 2.22 | 2.11 | |
| Ev To Sales | 58.24 | 3.52 | 11.05 | 32.72 | 18.99 | 31.88 | |
| Free Cash Flow Per Share | 0.76 | (0.85) | (0.91) | (0.9) | (0.72) | (0.76) | |
| Roic | 0.16 | (0.29) | (0.34) | (0.42) | (0.33) | (0.35) | |
| Net Income Per Share | 0.64 | (0.86) | (0.97) | (0.85) | (0.64) | (0.67) | |
| Payables Turnover | 355.15 | 27.24 | 31.09 | 64.95 | 32.52 | 43.9 | |
| Sales General And Administrative To Revenue | 1.05 | 0.0849 | 0.72 | 4.01 | 0.71 | 0.61 | |
| Research And Ddevelopement To Revenue | 6.15 | 0.45 | 3.86 | 15.33 | 3.69 | 2.82 | |
| Capex To Revenue | 0.26 | 0.017 | 0.11 | 0.31 | 0.0541 | 0.0738 | |
| Cash Per Share | 4.09 | 3.14 | 2.64 | 1.47 | 1.22 | 1.64 | |
| Pocfratio | 10.54 | (5.53) | (5.15) | (2.14) | (5.89) | (6.19) | |
| Interest Coverage | 23.51 | (332.93) | (135.99) | (199.57) | (304.68) | (289.45) | |
| Capex To Operating Cash Flow | 0.0341 | (0.0287) | (0.0401) | (0.0168) | (0.0133) | (0.0139) | |
| Pfcf Ratio | 10.91 | (5.38) | (4.95) | (2.11) | (5.82) | (6.11) | |
| Days Payables Outstanding | 1.03 | 13.4 | 11.74 | 5.62 | 11.22 | 10.66 | |
| Income Quality | 1.22 | 0.96 | 0.9 | 1.04 | 1.11 | 0.73 | |
| Ev To Operating Cash Flow | 7.08 | (2.87) | (3.94) | (1.75) | (4.65) | (4.89) | |
| Pe Ratio | 12.8 | (5.3) | (4.63) | (2.23) | (6.56) | (6.89) | |
| Ev To Free Cash Flow | 7.33 | (2.79) | (3.79) | (1.72) | (4.59) | (4.82) | |
| Earnings Yield | 0.0781 | (0.19) | (0.22) | (0.45) | (0.15) | (0.16) | |
| Net Debt To E B I T D A | (4.28) | 2.59 | 1.03 | 0.42 | 1.45 | 2.88 | |
| Current Ratio | 16.72 | 16.53 | 10.12 | 11.16 | 9.22 | 9.35 | |
| Tangible Book Value Per Share | 3.86 | 3.0 | 2.42 | 1.42 | 1.3 | 1.57 | |
| Receivables Turnover | 1.75 | 101.39 | 9.7 | 4.92 | 0.98 | 0.93 | |
| Graham Number | 7.48 | 7.63 | 8.24 | 6.21 | 5.23 | 4.01 | |
| Shareholders Equity Per Share | 3.86 | 3.0 | 3.1 | 2.02 | 1.9 | 1.7 | |
| Capex Per Share | 0.0267 | 0.0237 | 0.0352 | 0.0148 | 0.009458 | 0.0147 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.